×
X4 Pharmaceuticals EBIT 2016-2025 | XFOR
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
X4 Pharmaceuticals ebit from 2016 to 2025. Ebit can be defined as earnings before interest and taxes.
View More
X4 Pharmaceuticals EBIT 2016-2025 | XFOR
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
X4 Pharmaceuticals ebit from 2016 to 2025. Ebit can be defined as earnings before interest and taxes.
Related Stocks
Company Name
Market
Cap
AstraZeneca (AZN)
$218.6B
Amgen (AMGN)
$164.4B
Gilead Sciences (GILD)
$137B
Vertex Pharmaceuticals (VRTX)
$120.7B
Bristol Myers Squibb (BMY)
$97.7B
CSL (CSLLY)
$84.2B
GSK (GSK)
$75.8B
Regeneron Pharmaceuticals (REGN)
$60.6B
Alnylam Pharmaceuticals (ALNY)
$42.4B
Argenex SE (ARGX)
$35B
BioNTech SE (BNTX)
$26.8B
Royalty Pharma (RPRX)
$20.3B
Insmed (INSM)
$19.5B
Biogen (BIIB)
$18.7B
Illumina (ILMN)
$16.2B
Genmab (GMAB)
$14B
Genmab (GNMSF)
$13.8B
Incyte (INCY)
$13.3B
Moderna (MRNA)
$12.7B
Exelixis (EXEL)
$12.1B
BioMarin Pharmaceutical (BMRN)
$11.4B
QIAGEN (QGEN)
$11B
Swedish Orphan Biovitrum (BIOVF)
$10.6B
Ascendis Pharma (ASND)
$10.1B
Exact Sciences (EXAS)
$9.4B
Verona Pharma American Depositary Share (VRNA)
$8.9B
Blueprint Medicines (BPMC)
$8.3B
Bio-Techne Corp (TECH)
$8.3B
Legend Biotech (LEGN)
$8.1B
Roivant Sciences (ROIV)
$7.8B